A validation set using CD8+ T cell immunochemical staining demonstrated an immune profile similar to the previous two data sets for EGFR rare mutations, and a better prognosis for these cancer types than L858R and exon 19 deletions, with PD-1/PD-L1 inhibitor treatment. This evidence concerns the gene CD8A and cancer.